Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism-Reference-Cited by-同舟云学术

Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism

Published:2010-10 Issue:1 Volume:401 Page:149-153
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Flück Christa E.,Mullis Primus E.,Pandey Amit V.

Funder

The Swiss National Science Foundation

Novartis Foundation for Biology and Medicine

Roche Research Foundation

Swiss Society for Endocrinology & Diabetology

Bern University Research Foundation

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference45 articles.

1. Substrates of human hepatic cytochrome P450 3A4;Li;Toxicology,1995

2. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians;Shimada;J. Pharmacol. Exp. Ther.,1994

3. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition;Dresser;Clin. Pharmacokinet.,2000

4. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs;Zhou;Clin. Pharmacokinet.,2005

5. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases a new variant of congenital adrenal hyperplasia;Peterson;N. Engl. J. Med.,1985

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling;European Journal of Pharmacology;2024-04

2. Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain;Journal of Biological Chemistry;2023-09

3. Diagnostic challenges and management advances in cytochrome P450 oxidoreductase deficiency, a rare form of congenital adrenal hyperplasia, with 46, XX karyotype;Frontiers in Endocrinology;2023-08-11

4. Computational identification and analysis of deleterious non-synonymous single nucleotide polymorphisms (nsSNPs) in the human POR gene: a structural and functional impact;Journal of Biomolecular Structure and Dynamics;2023-05-12

5. P450 oxidoreductase deficiency;Genetic Steroid Disorders;2023